This series on “The Pathogenesis of Hepatic Fibrosis: Basic Facts and Clinical Challenges” is edited by Prof. Ralf Weiskirchen, Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, Aachen, Germany. The main purposes of this series are 1) this series summarizes and presents novel data on the pathogenesis of hepatic disease, 2) this series aims to bridge the gap between new re-search findings and clinical practice, 3) this series presents novel hypotheses and ideas that fos-ter the debate on new innovative concepts in basic and clinical hepatology.
Ralf Weiskirchen, PhD
Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, Aachen, Germany
Professor Ralf Weiskirchen is head of the Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC) at the RWTH Aachen University.
He is a basic scientist with a major research focus on the analysis of molecular mechanisms underlying the pathogenesis of hepatic fibrosis. During his work he intensively studies general aspects of cytokine and chemokine activities and their signaling pathways in disease initiation and progression. The long-term objective of his work is to translate experimental findings into novel diagnostic or therapeutic strat-egies. In his scientific career, he has authored until now about 270 original articles, 120 re-views/editorials, and 35 book chapters. Moreover, he gave a large number of presentations and lectures at medical and scientific conferences. He is an editorial board member of a wealth of journals, honorary reviewer for many national and international organizations, and active member of the German Associa-tion of the Study of the Liver (GASL) and the European Association for the Study of the Liver (EASL).
He is grateful to Digestive Medicine Research (DMR) offering him the possibility to edit the ongoing series “The Pathogenesis of Hepatic Fibrosis: Basic Facts and Clinical Challenges”.
- Prevalence of hepatic fibrosis
- Pathogenesis of hepatic fibrosis: Cellular and molecular drivers
- Assessment of liver fibrosis
- Experimental models of hepatic fibrogenesis
- Alcoholic liver disease: From Fibrosis to carcinogenesis
- Metabolic associated fatty liver disease (MAFLD): Old disease, new classification
- Viral hepatitis: A clinical view
- Autoimmune hepatitis: More than just a genetic disease
- Inflammasomes: Drivers of hepatic inflammation and fibrosis?
- Clinical concepts in treatment of hepatic fibrosis
- Traditional Chinese Medicine (TCM) in the treatment of hepatic fibrosis: Learing from nature
- Potential of exosomes for diagnosis and therapy of hepatic fibrosis
- Metal toxicity in the pathogenesis of hepatic fibrosis
- Novel insights in hepatic encephalopathy
- Gut microbiota and liver diseases: Facts and fictions
- Biomarkers in the assessment of hepatic fibrosis
- Vitamins and dietary supplements: Nutritional support for diseased liver?
- COVID-19 and liver fibrosis:
- Nanotechnology: Are there any clues for therapy of hepatic fibrosis?
- Antifibrotic drugs in clinical trials
- Predicting future challenges in therapy of hepatic fibrosis
The series “The Pathogenesis of Hepatic Fibrosis: Basic Facts and Clinical Challenges”was commis-sioned by the editorial office, Digestive Medicine Research (DMR) without any sponsorship or funding. Ralf Weiskirchen served as the unpaid Guest Editor for the series.